NCT04166773: A reported trial by Eli Lilly and Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04166773 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 19, 2019 |
| Completion date | Dec. 11, 2023 |
| Required reporting date | Dec. 10, 2024, midnight |
| Actual reporting date | Dec. 10, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |